Firm recently established promotion and distribution arrangements for Canada and India.
French genome engineering firm Cellectis bioresearch established a U.S. subsidiary located at the Cambridge Innovation Center in Cambridge, MA. The subsidiary will be responsible for promoting the firm’s targeted genome engineering products and services throughout the U.S.
Cellectis bioresearch specializes in cell-line development of meganuclease-based targeted integration products. It generates stable and isogenic cell lines for use in applications spanning drug discovery, gene function reserach, and protein production. The firm’s flagship cGPS® and cGPS Custom full kits comprise the required cell lines, integration matrices, and meganucleases for users to carry out targeted gene integration.
Establishment of the U.S. subsidiary is the latest phase in an obvious strategy by Cellectis bioresearch to promote its products and services globally. In September the firm teamed up with New Delhi-based Helix BioService to promote its products and services in India. Also in September it partnered with Ontario firm Cedarlane to promote its research kits in Canada. During the same month Cellectis bioresearch announced the $2.2 million cash acquisition of U.S.-based Cyto Pulse Sciences, which specializes in the development of electroporation technology.The latter’s Pulse Agile technology will be used in combination with the meganuclease platform.